ERBB2 and breast carcinoma: Human epidermal growth factor receptor 2 (HER2) status in patients with breast cancer has been categorized as positive or negative according to immunohistochemistry (IHC) and FISH following the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.1